ACE Inhibitors Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

The ACE Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected ACE Inhibitors Market Size During the Forecast Period?
The ACE Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected ACE Inhibitors Market Size During the Forecast Period?

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

What Are the High-Growth Segments in the ACE Inhibitors Market?
The ACE inhibitors market covered in this report is segmented -

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:
1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril
2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
3) By Phosphonate-Containing Agents: Fosinopril

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What Key Drivers Are Expected to Influence Future ACE Inhibitors Market Growth?
Driven by the escalating incidence of hypertension conditions, the ACE inhibitors market is predicted to expand in the future. Hypertension or high blood pressure is a state where the pressure levels inside blood vessels are unusually high. Angiotensin-converting enzyme inhibitors, or ACE inhibitors, represent a class of drugs employed to regulate hypertension. These drugs work by dilating blood vessels, thereby lowering blood pressure and boosting blood circulation. According to data from the World Health Organization in March 2023, nearly 1.28 billion adults globally, aged between 30 and 79, suffered from hypertension. Most of these adults were from low- and middle-income countries. Over the prior 30 years, the count of individuals between ages 30 and 79 with hypertension surged by 650 million. It's estimated that 46% of these adults remain undiagnosed and thus, unaware of their hypertensive condition. This growing rate of hypertensive conditions indeed pushes the growth of the ACE inhibitors market.

Which Companies Hold the Largest Share Across Different ACE Inhibitors Market Segments?
Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

What Trends Are Driving Growth in The ACE Inhibitors Market?
One major trend catching on in the ACE inhibitors market is the advent of product innovations. Companies within this space are strategically creating new products to solidify their market standing and gain a competitive edge. One such example occurred in February 2023 when US biopharmaceutical firm, Travere Therapeutics, revealed its FDA approval for FILSPARI (sparsentan). Standout as the first non-immunosuppressive treatment for IgA nephropathy (IgAN) patients, it joins the list of existing treatments including systemic glucocorticoids, ACE inhibitors, and antihypertensive medications, inclusive of angiotensin-receptor blockers (ARBs). Moreover, it is the single approved non-immunosuppressive medicine intended for daily oral intake by adults with primary IgAN, particularly those at the risk of fast disease progression, generally characterized by a UPCR less than 1.5 g/g and proteinuria.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

What Are the Emerging Geographies for The ACE Inhibitors Market Growth?
North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the ACE Inhibitors Market?
2. What is the CAGR expected in the ACE Inhibitors Market?
3. What Are the Key Innovations Transforming the ACE Inhibitors Industry?
4. Which Region Is Leading the ACE Inhibitors Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.